Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors

Trial Profile

Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs PQR 309 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PIQUR Therapeutics
  • Most Recent Events

    • 26 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results (n=41) from this trial and other trial (NCT02483858) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2016 Results of pharmacodynamic data (n=13) presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top